Member Directory
Mission Street have established a market-leading and rapidly growing Science and Innovation platform.
The current portfolio comprises over 1.5 million sq ft of committed projects in key strategic locations within Oxford, Cambridge and Bristol. Our innovative schemes and campuses are being developed speculatively with the first phases being the next available lab space in the respective locations.
Mission Street was founded in 2017 as an independent investor, developer and operator of Science and Innovation real estate. The company has since established itself as an industry leader working in conjunction with a highly experienced Advisory Board who bring invaluable insight and expertise from the perspective of our customers.
MISSION Therapeutics was founded in 2011. The company focuses on the biology of the DNA damage response (DDR) processes in cancer, optimising small molecule drugs to exploit synthetic lethality to selectively kill high unmet-need tumour types. Targeting deubiquitylating enzymes (DUBs) involved in regulating the DDR, MISSION has built an extensive proprietary biology and chemistry platform (Ubi-Sphere™) to support its discovery of inhibitors of DUBs. The application of DUB inhibitors extends across several therapeutic areas including neurodegeneration and infectious disease. The company is based at the Babraham Research Campus, Cambridge, UK.
Worried about how to protect your business from cybercrime, including ransomware attacks and theft of confidential business information? Every biomedical and life science company, large or small, is now a target for cyber criminals.
Service
This is proportionate, affordable, ongoing security, which protects businesses against cybercrime.
It starts with an assessment of your cyber risks. Mitigo then take care of the three areas needed to keep your business safe:
Technology
• On and off site technology assessments
• Penetration testing
• Vulnerability assessments and vulnerability scanning
• Controls and configuration
People competence
• E-learning
• Testing
• Simulated phishing
Governance
• Policies
• Cybersecurity handbook
• Control and risk management framework
• Risk management platform
This includes a dedicated expert client Helpdesk & Sandbox to which suspicious content may be sent.
Mitigo also provides Emergency cyber breach response, which includes:
• Emergency incident response and containment
• Forensics and investigation
• Assistance on reporting obligations
Certifications include:
• Cyber Essentials
• Cyber Essentials Plus
• IASME Governance
• ISO 27001
Mitigo is offering One Nucleus members a free cybersecurity assessment to help you understand the areas of your business that are most vulnerable to attack.
Listen to The Mitigo Q&A: The Importance of Independent Assurance - https://on.soundcloud.com/r4xQp
Find out more about Mitigo’s cybersecurity solution:
https://mitigogroup.com/partnership-pages/one-nucleus/
0209 8191 2053
onenucleus@mitigogroup.com
Drug Discovery
Clinical stage drug development company, bringing a stratified approach to neuroscience drug repurposing using digital biomarkers
MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, NJ, USA. MSD delivers vaccines, medications, and consumer and animal health products that save and improve the lives of millions around the world. MSD offers therapies for the treatment of cardiovascular disease, high blood pressure, elevated cholesterol levels, diabetes, cancer, benign prostatic hypertrophy, asthma and allergies, arthritis, pain, migraine, glaucoma, osteoporosis, women's health, infectious diseases (antibiotic, antifungal, and antiviral agents) and vaccines to prevent childhood diseases, human papilloma virus, rotavirus, shingles, and hepatitis A, B and C. Worldwide product sales in 2011 were $48 billion.
In MultiplAI Health we are developing a liquid biopsy for cardiovascular diseases based on RNA sequencing of the peripheral blood and analyzed through artificial intelligence. We believe that precise cardiovascular medicine can be found in a simple blood test.
Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection through the utilization of a novel, non-invasive procedure called liquid biopsy.